| Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma SJ Schuster, MR Bishop, CS Tam, EK Waller, P Borchmann, JP McGuirk, ... New England Journal of Medicine 380 (1), 45-56, 2019 | 3198 | 2019 |
| CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by … M Pfreundschuh, L Trümper, A Österborg, R Pettengell, M Trneny, K Imrie, ... The lancet oncology 7 (5), 379-391, 2006 | 2511 | 2006 |
| Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial M Hallek, K Fischer, G Fingerle-Rowson, AM Fink, R Busch, J Mayer, ... The Lancet 376 (9747), 1164-1174, 2010 | 2380 | 2010 |
| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, ... New England Journal of Medicine 371 (3), 213-223, 2014 | 1916 | 2014 |
| bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation TJ McDonnell, N Deane, FM Platt, G Nunez, U Jaeger, JP McKearn, ... Cell 57 (1), 79-88, 1989 | 1605 | 1989 |
| Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia JF Seymour, TJ Kipps, B Eichhorst, P Hillmen, J D’Rozario, S Assouline, ... New England Journal of Medicine 378 (12), 1107-1120, 2018 | 938 | 2018 |
| Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia BF Eichhorst, R Busch, G Hopfinger, R Pasold, M Hensel, C Steinbrecher, ... Blood 107 (3), 885-891, 2006 | 935 | 2006 |
| CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the … M Pfreundschuh, E Kuhnt, L Trümper, A Österborg, M Trneny, L Shepherd, ... The lancet oncology 12 (11), 1013-1022, 2011 | 836 | 2011 |
| Alternative promoters and exons, somatic mutation and deregulation of the Bcl‐2‐Ig fusion gene in lymphoma. M Seto, U Jaeger, RD Hockett, W Graninger, S Bennett, P Goldman, ... The EMBO journal 7 (1), 123-131, 1988 | 648 | 1988 |
| Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial S Stilgenbauer, A Schnaiter, P Paschka, T Zenz, M Rossi, K Döhner, ... Blood, The Journal of the American Society of Hematology 123 (21), 3247-3254, 2014 | 626 | 2014 |
| How I treat autoimmune hemolytic anemias in adults K Lechner, U Jäger Blood, The Journal of the American Society of Hematology 116 (11), 1831-1838, 2010 | 430 | 2010 |
| Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion … AV Kurtova, K Balakrishnan, R Chen, W Ding, S Schnabl, MP Quiroga, ... Blood, The Journal of the American Society of Hematology 114 (20), 4441-4450, 2009 | 424 | 2009 |
| Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma T Munir, JR Brown, S O'Brien, JC Barrientos, PM Barr, NM Reddy, ... American journal of hematology 94 (12), 1353-1363, 2019 | 416 | 2019 |
| Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting U Jäger, W Barcellini, CM Broome, MA Gertz, A Hill, QA Hill, B Jilma, ... Blood reviews 41, 100648, 2020 | 385 | 2020 |
| Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas B Streubel, A Chott, D Huber, M Exner, U Jäger, O Wagner, ... New England Journal of Medicine 351 (3), 250-259, 2004 | 385 | 2004 |
| Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia N Pflug, J Bahlo, TD Shanafelt, BF Eichhorst, MA Bergmann, T Elter, ... Blood, The Journal of the American Society of Hematology 124 (1), 49-62, 2014 | 359 | 2014 |
| Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic … S Stilgenbauer, T Zenz, D Winkler, A Buehler, RF Schlenk, S Groner, ... Journal of Clinical Oncology 27 (24), 3994-4001, 2009 | 349 | 2009 |
| The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL IW Flinn, P Hillmen, M Montillo, Z Nagy, Á Illés, G Etienne, J Delgado, ... Blood, The Journal of the American Society of Hematology 132 (23), 2446-2455, 2018 | 343 | 2018 |
| Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R)(FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free … M Hallek, G Fingerle-Rowson, AM Fink, R Busch, J Mayer, M Hensel, ... Blood 112 (11), 325, 2008 | 343 | 2008 |
| Consensus statement on the use of rituximab in patients with rheumatoid arthritis JS Smolen, EC Keystone, P Emery, FC Breedveld, N Betteridge, ... Annals of the rheumatic diseases 66 (2), 143-150, 2007 | 331 | 2007 |
